• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jane J. Kim, PhD

Publications

  • Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ.
    An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Vaccine. 2015 Mar 12.
    25770785
  • Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, Cremer ML, Kim JJ.
    The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador.
    Int J Cancer. 2015 Jan 14.
    25639903
  • Burger EA, Kim JJ.
    The value of improving failures within a cervical cancer screening program: An example from Norway.
    Int J Cancer. 2014 Mar 11.
    24615416
  • Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.
    Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys.
    PLoS ONE. 2014;9(3):e89974.
    24651645
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, .
    Comprehensive control of human papillomavirus infections and related diseases.
    Vaccine. 2013 Dec 31;31 Suppl 7:H1-31.
    24332295
  • Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.
    Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Vaccine. 2013 Dec 29;31 Suppl 5:F60-72.
    24331749
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, .
    Comprehensive control of human papillomavirus infections and related diseases.
    Vaccine. 2013 Dec 29;31 Suppl 5:F1-31.
    24331745
  • Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, Adewole IF, Awolude OA, Parham G, de Sanjosé S, Bosch FX.
    Recommendations for cervical cancer prevention in sub-saharan Africa.
    Vaccine. 2013 Dec 29;31 Suppl 5:F73-4.
    24331750
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, .
    Comprehensive control of human papillomavirus infections and related diseases.
    Vaccine. 2013 Dec 30;31 Suppl 6:G1-31.
    24331817
  • Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.
    Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Vaccine. 2013 Dec 30;31 Suppl 6:G65-77.
    24331822
  • Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ.
    Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Vaccine. 2013 Dec 31;31 Suppl 7:H71-9.
    24332299
  • Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX.
    Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer.
    Vaccine. 2013 Dec 30;31 Suppl 6:G78-9.
    24331823
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, .
    Comprehensive control of human papillomavirus infections and related diseases.
    Vaccine. 2013 Nov 22;31 Suppl 8:I1-31.
    24229716
  • Kim JJ, Sharma M, Ortendahl J.
    Optimal interval for routine cytologic screening in the United States.
    JAMA Intern Med. 2013 Feb 11;173(3):241-2.
    23530274
  • Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ.
    Modeling preventative strategies against human papillomavirus-related disease in developed countries.
    Vaccine. 2012 Nov 20;30 Suppl 5:F157-67.
    23199959
  • Kiatpongsan S, Campos NG, Kim JJ.
    Potential benefits of second-generation human papillomavirus vaccines.
    PLoS ONE. 2012;7(11):e48426.
    23144879
  • Sharma M, Bruni L, Diaz M, Castellsagué X, Sanjosé SD, Bosch FX, Kim JJ.
    Using HPV prevalence to predict cervical cancer incidence.
    Int J Cancer. 2012 Sep 11.
    22965284
  • Kim JJ,Goldie SJ.
    Health and economic implications of HPV vaccination in the United States.
    N Engl J Med. 2008 Aug 21;359(8):821-32.
    18716299